Innovations for Next-Generation Antibody-Drug Conjugates (eBook, PDF)
112,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
56 °P sammeln
  • Format: PDF

Focus on next-generation ADCs for oncology and other diseases
Description & analysis of current technological innovations for ADCs
ADC clinical development in the context of immuno-oncology

  • Geräte: PC
  • ohne Kopierschutz
  • eBook Hilfe
  • Größe: 10.26MB
Andere Kunden interessierten sich auch für
Produktbeschreibung
Focus on next-generation ADCs for oncology and other diseases

Description & analysis of current technological innovations for ADCs

ADC clinical development in the context of immuno-oncology

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Autorenporträt
Marc Damelin is Senior Director, Biology at Mersana Therapeutics in Cambridge, Massachusetts. His group is responsible for the discovery of therapeutic ADCs enabled by Mersana's proprietary linker-payload-scaffold technologies. Prior, Marc spent 10 years at Pfizer Inc. in the Oncology Research Unit, where he led ADC discovery teams and ultimately oversaw the ADC portfolio. He received his Ph.D. in Biophysics from Harvard University and conducted postdoctoral research at Columbia University Medical School as a Fellow of the Damon Runyon Cancer Research Foundation.